148.79 USD
+0.26 (+0.18%)
At close: Jan 30, 2026
153 USD
+4.21 (+2.83%)
After Hours: 1/30/2026, 8:09:40 PM
We assign a fundamental rating of 7 out of 10 to NUTX. NUTX was compared to 103 industry peers in the Health Care Providers & Services industry. While NUTX has a great health rating, its profitability is only average at the moment. NUTX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make NUTX a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
- In the past year NUTX was profitable.
- NUTX had a positive operating cash flow in the past year.
- In the past 5 years NUTX reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: NUTX reported negative operating cash flow in multiple years.
1.2 Ratios
- NUTX has a better Return On Assets (11.83%) than 95.15% of its industry peers.
- With an excellent Return On Equity value of 35.96%, NUTX belongs to the best of the industry, outperforming 95.15% of the companies in the same industry.
- NUTX has a Return On Invested Capital of 38.79%. This is amongst the best in the industry. NUTX outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROIC | 38.79% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NUTX's Profit Margin of 11.63% is amongst the best of the industry. NUTX outperforms 96.12% of its industry peers.
- With an excellent Operating Margin value of 35.72%, NUTX belongs to the best of the industry, outperforming 99.03% of the companies in the same industry.
- With a decent Gross Margin value of 55.01%, NUTX is doing good in the industry, outperforming 78.64% of the companies in the same industry.
- In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NUTX is creating value.
- Compared to 1 year ago, NUTX has more shares outstanding
- NUTX has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, NUTX has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.26 indicates that NUTX is not in any danger for bankruptcy at the moment.
- With a decent Altman-Z score value of 3.26, NUTX is doing good in the industry, outperforming 69.90% of the companies in the same industry.
- NUTX has a debt to FCF ratio of 1.87. This is a very positive value and a sign of high solvency as it would only need 1.87 years to pay back of all of its debts.
- NUTX has a better Debt to FCF ratio (1.87) than 84.47% of its industry peers.
- NUTX has a Debt/Equity ratio of 0.95. This is a neutral value indicating NUTX is somewhat dependend on debt financing.
- NUTX has a Debt to Equity ratio (0.95) which is comparable to the rest of the industry.
- Even though the debt/equity ratio score it not favorable for NUTX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 3.26 |
ROIC/WACC4.83
WACC8.03%
2.3 Liquidity
- A Current Ratio of 3.20 indicates that NUTX has no problem at all paying its short term obligations.
- NUTX has a better Current ratio (3.20) than 84.47% of its industry peers.
- NUTX has a Quick Ratio of 3.18. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of NUTX (3.18) is better than 85.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
- NUTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 873.64%, which is quite impressive.
- NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 236.03%.
- Measured over the past years, NUTX shows a very strong growth in Revenue. The Revenue has been growing by 222.96% on average per year.
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
3.2 Future
- NUTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.72% yearly.
- Based on estimates for the next years, NUTX will show a very strong growth in Revenue. The Revenue will grow by 51.11% on average per year.
EPS Next Y78.24%
EPS Next 2Y56.64%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue Next Year223.7%
Revenue Next 2Y83.21%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 8.05 indicates a reasonable valuation of NUTX.
- Compared to the rest of the industry, the Price/Earnings ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 95.15% of the companies listed in the same industry.
- NUTX is valuated cheaply when we compare the Price/Earnings ratio to 28.30, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 6.95, the valuation of NUTX can be described as very cheap.
- Based on the Price/Forward Earnings ratio, NUTX is valued cheaply inside the industry as 97.09% of the companies are valued more expensively.
- NUTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.05 | ||
| Fwd PE | 6.95 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NUTX is valued cheaper than 98.06% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 95.15% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.04 | ||
| EV/EBITDA | 3.25 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of NUTX may justify a higher PE ratio.
- NUTX's earnings are expected to grow with 44.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y56.64%
EPS Next 3Y44.72%
5. Dividend
5.1 Amount
- No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NUTEX HEALTH INC / NUTX FAQ
What is the ChartMill fundamental rating of NUTEX HEALTH INC (NUTX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to NUTX.
Can you provide the valuation status for NUTEX HEALTH INC?
ChartMill assigns a valuation rating of 9 / 10 to NUTEX HEALTH INC (NUTX). This can be considered as Undervalued.
What is the profitability of NUTX stock?
NUTEX HEALTH INC (NUTX) has a profitability rating of 6 / 10.
What is the expected EPS growth for NUTEX HEALTH INC (NUTX) stock?
The Earnings per Share (EPS) of NUTEX HEALTH INC (NUTX) is expected to grow by 78.24% in the next year.
How sustainable is the dividend of NUTEX HEALTH INC (NUTX) stock?
The dividend rating of NUTEX HEALTH INC (NUTX) is 0 / 10 and the dividend payout ratio is 39.41%.